Eos Senolytix
CompanyUnited States
Eos Senolytix develops 4 assets, the furthest preclinical (PTC-2105 in obesity). Mostly peptide; based in the United States.
- 4
- Assets
- Furthest stage
- Preclinical
- Raised
- US$750k
- 0
- Trials
- 0
- Signals
Pipeline
4Targets declining mitochondrial membrane potential to restore mitochondrial efficiency and induce senescent-cell apoptosis.
Preclinical, Peptide, obesity, sarcopenia
Targets declining mitochondrial membrane potential to restore mitochondrial efficiency and induce senescent-cell apoptosis.
Preclinical, Peptide
Targets mitochondrial membrane potential to enhance mitochondrial efficiency and ATP production in aging cells.
Stage not known, Peptide
1 more asset
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants1
- People7
- Signals1
- Similar companies6